Posts

A potential disease-modifying treatment for osteoarthritis from Cynata Therapeutics

/in ,

A potential disease-modifying treatment for osteoarthritis from Cynata Therapeutics Osteoarthritis is a chronic inflammatory joint disease that causes pain and disability, affecting over two million people in Australia and over 500 million people worldwide. Currently, there are no approved disease-modifying therapies for osteoarthritis, with treatment options limited to symptom management. Cynata is developing CYP-004, our Cymerus™ off-the-shelf iPSC-derived […]

Read more

Cynata Therapeutics release its Appendix 4E and Annual Report

/in ,

Cynata Therapeutics release its Appendix 4E and Annual Report Cynata Therapeutics has released its Appendix 4E and Annual Report, reflecting a year of strong momentum and significant progress across its clinical pipeline. As Independent Chair, Dr Geoff Brooke states, “Cynata is entering what I believe will be the most pivotal year in our history. Within […]

Read more

Phase 2 clinical trial of CYP-001 for treating high risk acute graft-versus-host disease

/in ,

Phase 2 clinical trial of CYP-001 for treating high risk acute graft-versus-host disease Earlier this week at the Australia and New Zealand Cellular Therapy and Transplant Conference (ANZTCT), Dr Ashleigh Scott of Cynata Therapeutics presented their latest clinical progress: a Phase 2 randomised, double-blind, placebo-controlled trial of CYP-001 for high-risk acute graft-versus-host disease (HR-aGvHD). CYP-001, manufactured with its proprietary Cymerus® technology, delivers consistent, high-quality […]

Read more

Licensing partnership in Saudi Arabia for Dapsone 5% Gel

/in ,

Licensing partnership in Saudi Arabia for Dapsone 5% Gel Melbourne, Australia; 31 July 2025; Acrux Limited (ASX: ACR) Acrux has executed a Sales, Marketing, Distribution and License Agreement with Servacure Trading W.L.L. (‘Servacure’) for Dapsone 5%, Gel for Saudi Arabia. Dapsone 5%, Gel was developed Acrux and was successfully launched through a licensee in […]

Read more

CalciMedica announces publication in the American Journal of Nephrology discussing design and rationale of Phase 2 KOURAGE trial of Auxora™ in AKI with respiratory failure

/in

CalciMedica announces publication in the American Journal of Nephrology discussing design and rationale of Phase 2 KOURAGE trial of Auxora™ in AKI with respiratory failure LA JOLLA, Calif., June 25, 2025 /PRNewswire/ — CalciMedica Inc. (“CalciMedica” or the “Company”) (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and […]

Read more

How Cynata Therapeutics is unlocking the power of iPSCs to transform regenerative medicine

/in ,

How Cynata Therapeutics is unlocking the power of iPSCs to transform regenerative medicine Cynata Therapeutics, a Melbourne, Australia-based regenerative medicine company, is pioneering a new era in cell therapy with its Cymerus platform. Built on the foundation of induced pluripotent stem cell (iPSC) technology, Cynata’s approach offers a transformative alternative to traditional mesenchymal stem cell […]

Read more

Promising efficacy data in preclinical studies of Cymerus MSCs in heart disease

/in ,

Promising efficacy data in preclinical studies of Cymerus MSCs in heart disease Melbourne, Australia; 7 April 2025 Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”,or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, today announced positive efficacy data observed in preclinical studies conducted with Cynata’s Cymerus™ iPSC[1]-derived MSCs[2] in models of ischaemic heart disease. MSCs […]

Read more

Armata Pharmaceuticals Announces Encouraging Results from the Phase 2 Tailwind Study

/in

Armata Pharmaceuticals Announces Encouraging Results from the Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection Results demonstrate that inhaled AP-PA02 provides a durable reduction of Pseudomonas aeruginosa in the lung, with a favorable safety and tolerability profile LOS ANGELES, Dec. 19, 2024 /PRNewswire/ — Armata Pharmaceuticals, Inc. […]

Read more

Armata Pharmaceuticals Announces First Patient Dosed in the Phase 2a Portion of the Phase 1b/2a ‘diSArm’ Study of AP-SA02 in Adults with Bacteremia Due to Staphylococcus aureus

/in

Initiation of the Phase 2a portion follows DRC review of positive safety and tolerability data from recently completed Phase 1b portion Study being conducted in partnership with the U.S. Department of Defense LOS ANGELES, Sept. 26, 2023 /Link here/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for […]

Read more

CalciMedica Announces Upcoming Presentations and Events in September

/in

LA JOLLA, Calif., Sept. 6, 2023 /Link here/ — CalciMedica Inc. (“CalciMedica”) (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that Rachel Leheny, Ph.D., Chief Executive Officer, will participate in a presentation at the H.C. Wainwright 25th […]

Read more